Dataset Information

Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy.

ABSTRACT:

Objective

To show cancer association is a risk factor other than statin exposure for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase autoantibody-positive (anti-HMGCR Ab+) myopathy.

Methods

We analyzed the clinical features and courses of 33 patients (23 female and 10 male) with anti-HMGCR Ab+ myopathy among 621 consecutive patients with idiopathic inflammatory myopathies.

Results

Among the 33 patients, 7 (21%) were statin-exposed and 26 were statin-naive. In relation with cancer, there were 12 patients (statin-exposed, n = 4) with cancers detected within 3 years of myopathy diagnosis (cancer association), 3 patients (all statin-naive) with cancers detected more than 3 years before myopathy diagnosis (cancer history), 10 cancer-free patients followed up for more than 3 years (all statin-naive), and 8 patients without cancer detection but followed up for less than 3 years (statin-exposed, n = 3). Therefore, 12 patients with cancer association (36%) formed a larger group than that of 7 statin-exposed patients (21%). Among 12 patients with cancer association, 92% had cancer detection within 1 year of myopathy diagnosis (after 1.3 years in the remaining patient), 83% had advanced cancers, and 75% died of cancers within 2.7 years. Of interest, 1 patient with cancer history had sustained increase in creatine kinase level over 12 years from cancer removal to the development of weakness.

Conclusions

Patients with cancer association formed a large group with poor prognosis in our series of patients with anti-HMGCR Ab+ myopathy. The close synchronous occurrence of cancers and myopathies suggested that cancer association is one of the risk factors for developing anti-HMGCR Ab+ myopathy.

SUBMITTER: Kadoya M

PROVIDER: S-EPMC5056647 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy.

Kadoya Masato M Hida Ayumi A Hashimoto Maeda Meiko M Taira Kenichiro K Ikenaga Chiseko C Uchio Naohiro N Kubota Akatsuki A Kaida Kenichi K Miwa Yusuke Y Kurasawa Kazuhiro K Shimada Hiroyuki H Sonoo Masahiro M Chiba Atsuro A Shiio Yasushi Y Uesaka Yoshikazu Y Sakurai Yasuhisa Y Izumi Toru T Inoue Manami M Kwak Shin S Tsuji Shoji S Shimizu Jun J

Neurology(R) neuroimmunology & neuroinflammation 20161007 6

<h4>Objective</h4>To show cancer association is a risk factor other than statin exposure for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase autoantibody-positive (anti-HMGCR Ab+) myopathy.<h4>Methods</h4>We analyzed the clinical features and courses of 33 patients (23 female and 10 male) with anti-HMGCR Ab+ myopathy among 621 consecutive patients with idiopathic inflammatory myopathies.<h4>Results</h4>Among the 33 patients, 7 (21%) were statin-exposed and 26 were statin-naive. In relation ...[more]

PMID: 27761483

Similar Datasets

Project description:ImportanceAutoimmune gastritis is an alternative cause of gastric carcinogenesis. This cause may be gaining importance with declining prevalence of chronic Helicobacter pylori infection.ObjectiveTo determine the association of prediagnostic autoantibodies to gastric mucosa with gastric cancer (GC) risk.Design, setting, and participantsThis cohort study used nested GC case-control analyses within separate Finnish cohorts of women of reproductive age (Finnish Maternity Cohort [FMC]; born 1938-1989) and older men (Alpha-Tocopherol, Beta-Carotene Cancer Prevention [ATBC] Study; born 1916-1939). There were 529 and 457 matched pairs from the FMC and ATBC Study, respectively, with mean participant ages of 30.5 and 57.5 years and medians of 17 and 11 years from baseline to cancer diagnosis. Data analyses were performed between August 2019 and November 2020.ExposuresAntiparietal cell antibodies (APCAs), anti-intrinsic factor antibodies, and anti-H pylori antibodies were measured in baseline serum using immunoassays.Main outcomes and measuresAutoantibody associations were estimated by odds ratios (ORs) and 95% CIs.ResultsOf the 529 control participants in the FMC and 457 control participants in the ATBC Study, 53 (10%) women and 35 (7.7%) men were APCA seropositive, respectively, whereas 146 (28%) women and 329 (72%) men were H pylori seropositive. In the FMC, APCA seropositivity was statistically significantly associated with GC risk among H pylori-seronegative women (OR, 5.52; 95% CI, 3.16-9.64) but not H pylori-seropositive women (OR, 1.29; 95% CI, 0.64-2.60; P for interaction = .002). The APCA association with H pylori seronegativity was strongest for tumors in the fundus and corpus (OR, 24.84; 95% CI, 8.49-72.72). In the ATBC Study, APCA seropositivity was not associated with GC among either H pylori-seronegative men (OR, 0.99; 95% CI, 0.32-3.04) or H pylori-seropositive men (OR, 1.06; 95% CI, 0.60-1.88). In both cohorts, anti-intrinsic factor antibody seroprevalence was less than 2% among cases as well as controls and not statistically associated with GC risk.Conclusions and relevanceResults of this cohort study demonstrate that autoantibody positivity may reflect subclinical autoimmune gastritis in younger women. The findings among young females and corpus subsite align with increasing cancer incidence trends for these groups. Stronger autoimmune associations in H pylori-seronegative individuals support a model of autoimmune gastritis replacing H pylori as the driving factor.

Dataset Information

Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy.

Objective

Methods

Results

Conclusions

Publications

Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure